The BCR-ABL tyrosine kinase inhibitors (TKIs) are a component of anticancer treatment, and their use dramatically improved the overall survival of CML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.